FT : A $2bn falling-out in the global commodities trade

A $2bn falling-out in the global commodities trade

International commodity trading houses were long underestimated as serious players in finance, in part because they are complex and somewhat mysterious, including to financial regulators and the media.

That remains true even though the largest groups are powerful and profitable on the scale of mainstream financial institutions and deeply entwined with banks, from which they borrow heavily to finance their activities.

Now that insular realm is colliding with the relatively obscure world of trade credit in a $2bn legal battle, bringing groups that span steel mills and high finance into public view.

The FT has a deep dive into how a longtime business relationship between the Swiss commodities trading giant Glencore and the embattled iron ore trader Radiant World devolved into a bitter multibillion-dollar legal battle.

The groups began trading iron ore together around 2008, according to a $2bn legal claim Radiant filed in Singapore against three Glencore entities this week. Then in 2017 they struck a deal that would become costly.

That year a Glencore manager, Radiant founder Pinkesh Nahar and another trader devised an arrangement where Radiant and the affiliated companies would place derivatives trades with Glencore acting as the counterparty. Losses would be rolled forward rather than closed out. And critically, the traders would not be subject to the collateral requirements typical of such a trade.

This led to trouble in the summer of 2021 when iron ore prices climbed to record highs. Radiant and its affiliates had amassed large short positions on iron ore, which crystallised into losses. Glencore demanded repayment of $1.1bn, the lawsuit alleges.

That might’ve been Radiant’s downfall, but Nahar struck a deal with senior Glencore executives and the ensuing years marked a period of rapid growth. Under the deal, the commodities giant would continue working with Radiant, help it raise money and potentially buy a stake in the business that would help propel it to a $5bn valuation in five years, according to the lawsuit. In return, Radiant and its affiliates would slowly pay down the $1.1bn.

But that deal too went sour as Radiant came under pressure over alleged inconsistencies in the documentation underpinning its trades.

Radiant has alleged that any inconsistencies come down to an unusual arrangement with Glencore, which it claims sought to conceal the “true nature” of its relationship while under monitoring by the US Department of Justice as part of a guilty plea to bribery charges by the Anglo-Swiss group in 2022. 

Glencore is now among the chorus of banks and financial institutions that allege Radiant used false invoices to secure funding. Glencore said in July that it had cut Radiant off after almost two decades. Documents disclosed by Radiant suggest Glencore’s exposure stands at $480mn, the FT reported this month.

Nahar has claimed that Radiant remains solvent with more than $1bn of assets on its balance sheet, most of which are receivables. But documents related to a freezing order against Radiant obtained in London’s High Court paint a bleaker picture — there is $10,000 of cash left.

About a decade ago the financial world finally began taking commodity traders such as Glencore, Vitol and Trafigura seriously. Now a series of recent large collapses in trade finance may force lenders to pay closer attention to this once obscure corner of the market.

WSJ : Jana Partners Pushes Contact-Lens Maker Cooper to Replace Its CEO Medical-

Jana Partners Pushes Contact-Lens Maker Cooper to Replace Its CEO
Medical-device manufacturer requires urgent overhaul to address ‘chronic underperformance,’ letter says

  • Activist hedge fund Jana Partners sent a letter demanding that contact-lens maker Cooper Cos. replace its chief executive.
  • Jana Partners also urged Cooper Cos. to consider selling its core businesses.
  • The activist investor stated that Cooper Cos. requires an urgent overhaul to address chronic underperformance and poor inventory management.

Activist hedge fund Jana Partners wants contact-lens maker Cooper Cos. to replace its chief executive and weigh selling its core businesses.

The activist investor made the demands in a letter it sent the company Thursday that was viewed by The Wall Street Journal.

Cooper’s chief executive, Albert White, has held the role since 2018.

The details
Cooper had a market value of around $10 billion as of Thursday’s close after its shares have dropped around 16% in the past year.

The medical-device manufacturer makes contact lenses and vision-care products through its CooperVision segment and provides products and services for women’s health and fertility through CooperSurgical. CooperVision is one of the largest producers of soft contact lenses.

Jana said Cooper requires an urgent overhaul to address its “chronic underperformance” and inability to manage its inventory and capital spending. The activist investor called on the company to replace its CEO, appoint a new board chair, engage with potential buyers of the contact-lens business, and consider selling its fertility and medical-device assets.

The context
Jana is ramping up the pressure on Cooper after building a stake in the company roughly a year ago. At that point, it urged it to consider strategic alternatives including a potential deal to combine its contact-lens unit with rival Bausch + Lomb.

Since then, investor concern has weighed on the company’s shares, falling 28%. When Cooper reported its third-quarter earnings earlier this month, it said it is expanding its U.S. sales force to reach 5,000 additional eye-care offices.

Should Jana decide to run a proxy fight at Cooper, the window to nominate directors closes in early January, according to FactSet.

Jana earlier this year built a stake in Fiserv and pushed for changes to boost the payments company’s underperforming stock.

WSJ : Hackers Used Anthropic’s Claude to Break Into OpenAI A bug-hunting indepen

Hackers Used Anthropic’s Claude to Break Into OpenAI
A bug-hunting independent security research team accessed OpenAI’s internal code system, exposing growing risks in automated cyber threats

  • Independent security researchers used Anthropic’s Claude software to gain access to an OpenAI employee’s ChatGPT account.
  • The hack allowed the researchers to read files in OpenAI’s private software repository, which contains the company’s algorithmic secrets.
  • OpenAI paid the researchers a $6,500 bounty and said it has resolved the security issues uncovered by the hack.

Two weeks after a swarm of AI agents broke out of containment at OpenAI to hack the company Hugging Face, the ChatGPT maker learned about another AI-powered intrusion—and this time it was the target.

Independent security researchers had used Anthropic’s Claude software to gain access to an OpenAI employee’s ChatGPT account, giving them a way to read and suggest changes to the company’s private cache of software.

The team, who participated in an OpenAI bug-hunting program that offers a safe harbor for researchers to attempt to break into corporate systems, quickly reported their findings to the company. The team, to which OpenAI paid a $6,500 bounty, disclosed their work for the first time to The Wall Street Journal.

The new hack joins a long list of recent disclosures by leading technology companies and researchers alike of cyber intrusions aided by fast-evolving artificial-intelligence tools. Despite months of warnings about the capabilities of AI systems, the new intrusion shows how the complexity of today’s computer systems makes them difficult to defend.

OpenAI CEO Sam Altman and his peers on Saturday called for a pause in AI development, saying that it is moving too fast for companies building the technology to safely mitigate harms. OpenAI on Wednesday disclosed previously unreported safety incidents and announced new policies for how it plans to report such issues.

At a time when the U.S. is engaged in a race with China for AI supremacy, the researchers that hacked OpenAI said the attack suggests that advanced cyber-savvy teams backed by nation states have a very real chance of getting a peek at the country’s AI secrets.

“I don’t think we are as strong as Chinese threat actors,” said Mohan Pedhapati, chief technology officer with Hacktron AI, the security firm that did the research. “We’re just three guys with Claude and Codex subscriptions.”

OpenAI said the hackers had uncovered a pair of issues: one in a third-party service called Discourse that hosts OpenAI’s community discussion forum, and a second with the AI company itself. Both of these are now resolved, OpenAI said.

“We thank the researchers for contacting us and sharing their findings. We narrowed the permissions on Community sign-in tokens and revoked affected tokens and sessions,” the company said.

An Anthropic spokesman declined to comment.

Cyber researchers regularly participate in bug bounty programs, which stress-test major companies’ digital infrastructure.

The hack of OpenAI began on July 23, when Hacktron’s researchers found a bug in the way that the community-discussion forum Discourse processed certain image files. The researchers had access to a special version of Claude Opus 4.8, made available to qualified cybersecurity practitioners, and they asked it to write code that would exploit this bug in a cyberattack.

At first, it didn’t work. That evening, however, Anthropic released Opus 5 and by the next day, Claude had found a way to exploit the bug. The attack code it produced allowed the researchers to gain access to a Discourse server hosting OpenAI’s discussion forums, where they were able to access users’ authentication tokens, the unique digital strings of letters and numbers that allow people to gain access to online services.

To their surprise, these tokens were valid on ChatGPT, and some of them belonged to OpenAI employees. The tokens could also be used to access OpenAI’s GitHub service, a software repository.

Because they didn’t want to access sensitive data, the researchers can’t say for certain what the OpenAI source code system was used for, but they said it was named, “Monorepo.” Monorepo, according to people familiar with OpenAI’s architecture, is a large software repository of OpenAI’s algorithmic secrets.

It is the software equivalent of the company’s secret sauce, which makes its models faster and more efficient—but it isn’t thought to contain the model weights, which are the equivalent of OpenAI’s crown jewels, the people said. These are the trillions of numbers at the core of the large language models that help them understand which pieces of information to amplify and which to ignore.

Using ChatGPT as their interface, the researchers could read files in Monorepo. The researchers said they stopped their hack once they realized that they could access sensitive data, but not before they made what’s known as a pull request.

They instructed the chatbot to send a “pull request” or suggested change—to a documentation file in the repository. The team suggested an update that would have changed the documentation file to include the words “Hacktron AI Team PoC” and a link to the X accounts of Pedhapati and the company’s head of research Harsh Jaiswal. It was their proof that they had gained access to OpenAI’s secrets, they said.

The suggested change wasn’t accepted, the researchers said. OpenAI said its review of GitHub found “limited reads” of private-repository metadata and code changes.

Discourse said it fixed the security issue on July 25, the same day it was notified.

The hack demonstrates the complexity of defending corporate secrets in the age of AI hacking, said Joshua Saxe, the chief technology officer with the AI security company Abundant Security, who reviewed Hacktron AI’s report on the incident.

“The world’s software is rife with security bugs. The reason we haven’t discovered them all is because, until last year, there were only a few thousand people who were expert at finding those bugs,” he said.

Now AI agents are making that capability available to people who are less skilled, Saxe said.

Criminals are gaining access to these capabilities, too, according to the cybersecurity firm ThreatDown. In online forums, people can buy illicit access to the kind of cyber-enhanced accounts used by the Hacktron researchers for as little as $800, ThreatDown said.

After the July Hugging Face attack and the researchers’ hack, OpenAI did a serious security audit of its systems, the company’s president and co-founder, Greg Brockman, said this week. “We took 25% of our production engineers and said ‘Sorry, all your projects are on hold. You are now defending,’ ” he said. “And we found a number of serious issues and we fixed them.”

WSJ : When Weight Loss Isn’t the Goal of Taking a GLP-1 Doctors are exploring wh

When Weight Loss Isn’t the Goal of Taking a GLP-1
Doctors are exploring whether weight-loss drugs could also treat conditions such as endometriosis and Crohn’s disease

At 5 feet 11 inches and 138 pounds, Ali Balkey has always been thin.

So it might seem surprising that the 41-year-old Dallas, Texas, real-estate investor says she has been taking a compounded version of a GLP-1 since February.

It is most certainly not for weight loss. Balkey says she takes a microdose—a smaller amount than what’s normally prescribed—to help her manage pain and other symptoms from endometriosis, an inflammatory condition in which tissue becomes implanted outside the uterus, causing scarring, adhesions and pain.

Long used for weight loss and diabetes, the Food and Drug Administration has approved certain GLP-1s for additional uses, including obstructive sleep apnea, chronic kidney disease and severe fatty liver disease. Though widely considered safe for most people, the drugs can have side effects, such as gastrointestinal issues, muscle and bone loss and rare serious conditions like pancreatic inflammation. But the GLP-1s are increasingly being researched, used experimentally, and even prescribed off-label to treat a range of other conditions in which they show promise.

Dr. Andrea Vidali, a prominent endometriosis surgeon who works in Florida and New York, estimates that nearly one in five of his endometriosis patients, like Balkey, take a GLP-1 off-label, some prescribed by him and some who come in already taking them, mainly for pain and related symptoms.

Like most doctors, he only prescribes brand-name GLP-1s made by Eli Lilly and Novo rather than the compounded, copies versions made by special pharmacies and commonly sold by telehealth companies and med spas. When the brand-name drugs are prescribed off-label, they aren’t covered by insurance and can cost hundreds of dollars a month. But because patients are microdosing, one $499 Ozempic pen goes much farther, bringing the monthly cost well below that, says Vidali.

“I usually keep them on the microdose,” says Vidali. “Many of these patients are not overweight, some are normal weight or even underweight, so you don’t want them to lose weight or muscle mass.”

The GLP-1s aren’t treating the actual disease, says Vidali. Rather, their likely target is a nerve and immune system that has become oversensitized, he says.

“Mechanistically, the hypothesis is that it works in the periphery, with an anti-inflammatory effect on the nerves,” he says.

Vidali says prescribing GLP-1s off-label is becoming more mainstream, particularly in fertility practices, for women with polyendocrine metabolic ovarian syndrome, or PMOS, and related metabolic issues such as insulin resistance. Novo and Eli Lilly don’t support the off-label use of their GLP-1 medications.

Some studies conducted by academic researchers suggest GLP-1s may improve metabolic health and menstrual regularity in women with PMOS, particularly those who are overweight or have obesity. Patients with irritable bowel syndrome who took an experimental GLP-1 drug reported relief of acute pain and those with knee osteoarthritis and obesity have less knee pain though that can’t be separated from weight loss.

While the evidence is still preliminary, or in some cases anecdotal, demand to try a GLP-1 is high.

Dr. Diana Girnita, founder and CEO of Rheumatologist OnCall, a telemedicine practice in more than 20 states, has seen patients with conditions like rheumatoid arthritis, gout, psoriasis, and knee and hip osteoarthritis seek out GLP-1s. She estimates about 10% of the practice’s nearly 2,000 patients are on a GLP-1, with only a fraction of them using them truly off-label because they don’t have obesity or Type 2 diabetes.

Of her patients who take GLP-1s for such conditions, nearly 80% report less joint pain and better function, she said, though it can take three to six months for patients to see improvements in symptoms.

In patients who aren’t overweight, she is cautious, typically starting them on a six-month trial of a microdose. “What I watch for is lean mass loss, which matters more in someone with inflammatory arthritis than in the general population, because muscle is what protects the joint,” she says.

Dr. Louis Cohen, a gastroenterologist and associate professor at Mount Sinai in New York City, is studying whether tirzepatide—the active ingredient in Eli Lilly’s Zepbound and Mounjaro —can improve symptoms in patients with Crohn’s disease, a type of inflammatory bowel disease. He’s enrolling mostly normal weight patients in a small trial that will compare taking a GLP-1 with standard of care over six months.

Participants are taking standard doses of tirzepatide—not microdoses. They work closely with a nutritionist to monitor their weight and calorie intake.

“People sort of forget what GLP-1s are fundamentally,” says Cohen. “They promote absorption within the bowel so they slow down movement within the bowel but they also may stimulate the bowel to grow.”

While there is a decent amount of data showing that Crohn’s patients can tolerate GLP-1s, Cohen says he’s not yet prescribing them off-label for patients who don’t meet the criteria. He’s holding off until he sees trial data but is encouraged by reports that GLP-1s helped improve outcomes in patients with psoriasis, which has similar medical characteristics to Crohn’s.

While doctors and researchers explore GLP-1’s potential for other conditions, getting those uses approved can be challenging. Drug companies generally have to sponsor large clinical trials to receive FDA approval for additional indications, and insurers don’t typically cover a drug until it is FDA approved.

And while promising, some doctors are still cautious about off-label prescribing. Dr. Katherine H. Saunders, a clinical assistant professor of medicine at Weill Cornell Medicine and co-founder of FlyteHealth, a medical obesity-treatment company, says while she’s open-minded, she is not cavalier about prescribing GLP-1s for off-label use.

“The further we move from an FDA-approved indication, the higher the bar should be,” she says. “These are powerful medications, and enthusiasm should not get ahead of science.”

For most conditions, the evidence remains scarcer than it is for obesity, diabetes, and the other conditions for which GLP-1 drugs have been approved. One of the most compelling off-label uses of GLP-1s is in patients with alcohol use disorder and other addiction disorders, says Saunders.

A spokesperson for Eli Lilly said the company is studying additional uses for GLP-1s, including to treat substance abuse disorders, heart disease, asthma, and other neurological and immunologic conditions. A spokesperson for Novo said the company isn’t currently studying any additional uses for the GLP-1 medications on the market.

Balkey says she started taking GLP-1 after an endometriosis surgery with Vidali in January. Vidali mentioned that many of his patients were noticing improvements with a GLP-1.

“I had never really considered it because I have a low BMI,” Balkey says. She was nervous because she gets nauseous easily but hasn’t experienced any negative side effects.

“I’m the same weight,” she says. “I am intentional about making sure I’m eating enough and getting my protein.”

Balkey says she started seeing improvements in her symptoms within about two months, though acknowledges some of it is also attributable to the surgery.

“My life has dramatically improved,” she says. “I hope that we’re able to get funding for more research so that this type of treatment can be available.”

>>> US After Hours Summary: REXR +1.0% higher on earnings; STLD -4.2%, NUE -3.1%

After Hours Summary: REXR +1.0% higher on earnings; STLD -4.2%, NUE -3.1% lower on earnings

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance:REXR +1.0%

Companies trading higher in after hours in reaction to news:BWMX +4.5% (Disclosed insider purchases totaling about $2.3 million by the CEO, chairman and a director.), TMCI +3.8% (Reported five-year Lapiplasty data showing low recurrence and sustained patient improvement.), BRT +2.9% (Replenished its stock repurchase authorization to $10 million and disclosed $40 million of borrowing capacity under an amended facility.), INTA +2.5% (Launched a Celeste plug-in for ChatGPT Enterprise, integrating governed firm data into lawyers’ OpenAI workflows.), NHIC +1.9% (Shareholders approved the newcleo business combination, expected to close September 21.), PBYI +1.9% (Initiated Phase II ALISCA-Lung2 trial of alisertib plus paclitaxel in advanced small cell lung cancer.), PXED +1.6% (Agreed to acquire AI-powered workforce transformation platform Fuel50, with closing expected within 30 days.)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance:STLD -4.2%, NUE -3.1%

Companies trading lower in after hours in reaction to news:XENE -24.8% (Paused enrollment in depression studies after neuropsychiatric adverse events; X-NOVA2 data are now expected in Q1 2027.), MOD -1.5% (Cut SpinCo's pre-merger cash distribution to Modine to $159 million from $210 million ahead of Oct. 1 closing.), FRMI -1.0% (Secured court denial of former CEO Daniel Neugebauer’s bid to block board bylaws and annual-meeting nomination deadline.)

NYT : U.S. Intelligence Warns of China Theft Over Sale of F-35 Jets to Saudis In

U.S. Intelligence Warns of China Theft Over Sale of F-35 Jets to Saudis
Internal reports, including one from the Pentagon’s Defense Intelligence Agency, say China could acquire U.S. jet technology through spying or cooperation with Saudi Arabia.

U.S. intelligence officers have expressed concerns in internal reports about possible Chinese espionage related to a pending sale of dozens of advanced F-35 fighter jets to Saudi Arabia valued at $24 billion, according to American officials.

Intelligence analysts have raised the possibility that China could acquire F-35 jet technology through spying in Saudi Arabia or through its military and security partnership with the kingdom, the U.S. officials said.

One detailed report issued by the Pentagon’s Defense Intelligence Agency months ago discusses Chinese military access to Saudi bases and Saudi Arabia’s use of Chinese technology in its telecommunications infrastructure, an official said. It also questions whether the Americans and Saudis will be able to maintain secure sites for the F-35 technology, the official said.

That report has circulated among several administration agencies and congressional offices, as have assessments from other intelligence offices. The D.I.A. issued a more general report in the fall of 2025 on similar risks when the administration was discussing the possibility of the sales, The New York Times reported at the time.

President Trump then announced the sale the day before he hosted Crown Prince Mohammed bin Salman, the de facto leader of Saudi Arabia, at the White House in November.

The sale is at a more advanced stage now, and the newer D.I.A. report raises sharper concerns, including technical ones. The State Department sent the proposed sales package of 48 jets and a spare engine to two congressional committees in June to get informal approval. Some lawmakers and aides have been pressing the administration on the concerns raised by the intelligence agencies.

The U.S. officials spoke about the concerns among intelligence officials on the condition of anonymity because of sensitivities around espionage and military matters.

The State Department, the Pentagon and the Embassy of Saudi Arabia in Washington declined to comment. The White House and the Embassy of China did not reply to requests for comment.

U.S. intelligence agencies raised similar concerns internally during Mr. Trump’s first term after he agreed in 2020 to sell F-35 jets to the United Arab Emirates as part of a deal in which the Emirates would normalize relations with Israel.

It takes years to produce the jets, which are made by Lockheed Martin, and the Biden administration decided to review the sale well before production and delivery. Intelligence agencies raised the same issues at that time because the Emirates was strengthening its military, intelligence and technology ties with China. U.S. officials then ended the sales process.

Prince Mohammed has been trying to build up his military. He began a disastrous seven-year war against the Houthis in Yemen, one in which Saudi-led forces killed civilians with American bombs. The Saudi military has failed to ward off attacks from Iran in the current U.S.-Israeli war against Iran, and the Saudis and the Houthis, which are supported by Iran, have begun fighting again.

Prince Mohammed has long sought to buy F-35 jets from the United States, and Mr. Trump finally agreed last November. Saudi Arabia and the United States have had decades of military cooperation, and the kingdom is by far the largest buyer of American weapons and defense equipment.

But Saudi Arabia buys ballistic missiles from China, and the Chinese military is helping the Saudis learn to build ballistic missiles, set up production facilities and improve missile operations.

Democratic lawmakers sent President Joseph R. Biden Jr. a letter in June 2022 laying out their concerns over that program.

The recent Pentagon intelligence report said that only Saudi and American officers and contractors should have access to sites where F-35 technology would reside, a U.S. official said. Pentagon officials are especially concerned about protecting the advanced radar and surveillance technology of the F-35.

The intelligence analysts ask in the report whether Saudi Arabia would more broadly agree to limit contact with Chinese military and intelligence personnel and associated entities.

The report also questions whether Saudi officials would agree to remove equipment from Huawei and ZTE, two prominent Chinese technology companies, from telecommunications and router infrastructure and defense installations.

Some Israeli officials also have concerns about the deal, as they did when Mr. Trump proposed such sales to the Emirates. Israel is the only country in the Middle East that has F-35s, which it has deployed in airstrikes against Iran in recent years. Since the 1973 Arab-Israeli war, U.S. policymakers have tried to ensure that Israel maintains its “qualitative military edge” in the region, as mandated by Congress.

Previous administrations ran a highly classified, monthslong process to review whether proposed weapons sales to Arab nations in the region would violate that requirement.

Separately, the second Trump administration has continued to push through large arms sales to Israel, despite calls across the American political spectrum to end or severely decrease military support.

In several instances, Secretary of State Marco Rubio has bypassed the congressional approval process to expedite shipments of weapons to Israel, citing an emergency in the region. If congressional leaders do not give approval for the F-35 jet sales to Saudi Arabia, he could decide to do the same with that.

Mr. Trump has also agreed to help Saudi Arabia build a civilian nuclear program, a project that has raised its own security concerns because Prince Mohammed has vowed to build nuclear weapons if Iran does so.

The Information : Bridgewater’s Greg Jensen Calls for Regulating AI Firms Like S

Bridgewater’s Greg Jensen Calls for Regulating AI Firms Like Systemically Important Banks

The Takeaway
  • Greg Jensen calls for regulating major AI compute holders like systemically important banks.
  • Jensen warns of AI risks from open-source models and compute concentration.
  • Bridgewater sees AI infrastructure build-out largely priced in for stocks.

Greg Jensen, co–chief investment officer at Bridgewater Associates, thinks the top holders of AI compute warrant extra regulation, similar to what governs the world’s biggest financial institutions.

If a company controls more than, say, 5% of U.S. or global compute, it should be subject to heightened oversight, “like we do with systemically important banks,” Jensen said. In a wide-ranging interview, he also discussed Bridgewater’s growing use of AI in investing and where it still remains cautious, including leaving risk controls and trade execution to what he called “human-driven algorithms.”

As co-CIO at one of the world’s largest hedge fund firms, Jensen oversees Bridgewater’s Pure Alpha strategy, which makes computer-driven bets on big economic trends, as well as an AI skunkworks called AIA Labs. Jensen founded AIA in 2023 to develop an AI investing machine that can reason its way through markets and come up with winning trades. Bridgewater now has more than 80 employees devoted to the approach and a dedicated fund that uses AI to manage $4.5 billion.

Jensen, in other words, is a big proponent of AI and the benefits it can bring to the investing profession as well as society, he said in an interview. But he’s also worried about what AI can do if left unchecked, and he is calling for a laundry list of regulations and increased oversight.

As part of that, Jensen argues that slowing progress at the leading labs won’t be enough to control AI’s risks, which could also come from open-source models.

“There’s a huge problem with open-source models because you can train them. We do this at Bridgewater; it’s extremely effective reinforcement learning training on powerful open-source models,” he said. “It’s extremely powerful. A great technology, and at the same time clearly a very dangerous one.”

Jensen explained Bridgewater’s own experiences and challenges with AI, including how a model cheated on a test it had been given inside the firm, as well as its approach to managing its own AI infrastructure. Bridgewater rents all of its compute, he said, as opposed to other investment managers that have acquired their own graphics processing units or gotten involved in building data centers.

When it comes to actually investing in AI-linked companies, Bridgewater thinks much of the infrastructure build-out is priced into stocks now, and the firm is setting its sights on other trades.

AI Agenda Live SF 2026
Wed., September 23, 2026
San Francisco, CA
Buy tickets
“Overall, we have a very small position on the AI build-out at this point and are much more interested in the disruption and adoption trades now,” Jensen said.

This interview has been edited for length and clarity.

You’ve clearly been thinking about AI safety for some time—do the AI industry’s efforts to slow development address your concerns?

Any way you look at the evidence, it’s clear that the machines are reasoning in ways that are surprising to the designers, in ways that illustrate a desire in some sense to survive, a willingness to cheat, [a] willingness to lie. And that’s across labs. The OpenAI Hugging Face [breach] is an extreme example, but that’s happening all over the place. So we’re at this very, very dangerous point.

Slowing down the frontier labs is not nearly enough, meaning we have to think through the whole picture of what is happening. Start with understanding what’s happening, both for closed-source models [and] open-source models—the implications from a risk safety perspective are a big deal—and then thinking through the societal problems that are going to occur as a result of this technology.

So this is a good start, but there’s a lot more that we need to get working on now because the problems are going to keep coming at us at an increasing rate.

What else is needed?

There’s a huge problem with open-source models because you can train them. We do this at Bridgewater; it’s extremely effective reinforcement learning training on powerful open-source models. It’s extremely powerful. A great technology, and at the same time clearly a very dangerous one.

You don’t know what people are doing with them. There’s no way to track that, so it’s dangerous from that perspective. We haven’t even begun the conversation on how to deal with that issue.

And then we have to deal with the concentration of power. In two years, OpenAI and Anthropic are going to control 35% to 50% of the world’s compute. That’s a crazy outcome for a society to allow on something as powerful as compute. Would we let one entity control that much of some other form of energy or commodity?

Finally, I’d say, we need to be really clear as much as possible as to who is responsible for crimes committed with AI, and make sure that that’s well understood so that the people putting out things in a rush recognize the risk that they’re taking as corporations and individuals.

How do you stop the concentration of compute?

We should take anybody that has more than x percent, let’s say 5%, of the world’s or U.S.’s compute resources. Say, “OK, those are systemically important institutions—we’re going to put them into some sort of thing like we do with systemically important banks and say there’s going to be regulation.”

I also think it’s fine to say we’re going to have caps on how much you can own. There’s a cap on how many commodity futures you can own. There’s a cap on much less important things. We may be able to do that with current law—you may need new laws. Either way, let’s get going on sorting that out legally.

There should be a bipartisan recognition that you shouldn’t want monopolistic control on what I think most people will agree is one of the most important resources in the world.

What would you say to the critics who argue that would give China an edge?

I’m no big fan of government regulation, but if the problem’s big enough and society bears the risk, you need government regulation. No matter how much you might dislike it or find it a very hapless tool in many ways, you can’t get away from it if it’s [about something] extremely risky to society.

On the China race thing, I’d make a couple points. The reason China and open-source models are moving so quickly is in large part because they’re borrowing from the technology the frontier labs are putting out there—distilling them, stealing intellectual property and other things. If you slow down the frontier, you mechanically slow down others, because they’re copying those things. They don’t have the compute. They’re not actually creating models in the same way frontier labs are.

I also think the idea that China would never cooperate on such a thing is also misreading how China operates. I think that they are as interested in or more interested in controlling technology, making sure it doesn’t threaten their power and so on. There’s a lot of reason to believe there would be common ground if we chose to seek it.

Lastly, we should put regulatory standards on any model that enters the U.S. ecosystem. And that’ll slow down the revenue and the other things those labs need if we don’t come to some way of being able to regulate those labs at all.

Have you seen AI do things firsthand that concern you?

In terms of our use case, look, there is stuff that surprises me. Reinforcement learning on open-source models is better than I expected. It’s better than frontier in many ways. But if you turn that over and say what you could aim that technology at, it’s pretty easy to transfer that to other things that would be much more negative.

And we did have a result where one of the models cheated on our test. Obviously, people within the labs on the cutting edge have an even deeper window into things. But people that think they’re making this up for publicity or whatever, I believe that is a wrong view.

Wait, you had a model cheat? What task had you given it?

We have research projects where we build out a test of whether it can go achieve the types of things our human investors do. And the model went and it just found the answer key. It did that rather than doing the task.

What is Bridgewater’s AI infrastructure setup?

We don’t own our own compute. We’re renting it in a variety of ways, both literally renting [from cloud providers] for our own use and our own training models, and then using some of our partners’ compute, particularly for the most compute-intensive reinforcement learning tasks that we do.

Most of the best reinforcement learning tools, honestly, are not in those frontier labs. Thinking Machines has the best tools, and [there are] a few other partners that do the best work on reinforcement learning for others.

How much of a bottleneck is access to compute for you?

Where compute would be helpful, particularly when you look out into the future, is some of the stuff we have in the lab will require a significant amount of compute to put into real time. Compute is somewhat of a future potential bottleneck. Compute is not our main constraint.

Our most important constraint is creating great algorithms that actually reason and handle the problem of markets, which is that there’s not really that much information, there’s limited data, and the data in the future is not necessarily the data of the past. Even understanding that there are AIs in markets today, that’s just one example of something that’s changed, and you have to really question the value of past data given the change in the world.

So you need to reason across it, and those are the most important, hard algorithms to crack. Not even the labs have cracked this problem.

What models are you using?

You can think of [AIA] as many different agents. Some of those agents are fueled by the best frontier technology, some of them are best used for reinforcement learning for a particular task.…Sometimes you really want a broad intelligence. Sometimes you want your expert that really knows a sector. So we use different tools.

We’re constantly benchmarking. So it’s not like we’re locked into Anthropic or OpenAI—we’re constantly measuring their tools for the different tasks that we are building, the different components of the brain, and choosing the models that provide the best intelligence for those tasks.

How do you think about the data that you’re sharing with partners?

Carefully. We’ve worked hard on how to build this. For what it’s worth, we were one of the first people that moved a significant amount of intellectual property into the cloud more than 15 years ago or so with Amazon, and worked hard on their security outline for how to get comfortable doing that with Bridgewater’s algorithms and such. Similarly, we have worked with AI providers to get to agreements that we can feel comfortable with. And [we] move fast.

There are two types of risks. You could get too stuck on security such that you don’t make progress using the most effective tools, and you could be reckless with your intellectual property. And so we’ve worked hard on balancing those and made our determinations of which partners to use for what things.

Are you able to negotiate zero data retention with Anthropic?

I won’t get into all of our negotiations, but we’re getting the best terms that we can get comfortable with. And that is provider by provider, but we’re able to get terms that we think put us on the best footing for what we’re doing.

What is the best way to think about AIA Labs?

We built out our first kind of internal model by giving it case studies of all of [our] history, helping it reinforce and learn what are the causal relationships through history, then apply that learning to the future. And that’s when we set up AIA as a return stream, so as a fund. We basically got that done by the beginning of 2024. We’ve been managing money since then.

So now we have two factories, one where it’s human intuition supported by the best technology and more and more AI. And we have one where humans are training and controlling an AI, but the AI is actually making the investment decision, whether we’re long the yen or short stocks or whatever. They’re risk controlled by human controls, data acquisition is human controlled, but the actual investment decisions in the AIA fund are made by the machine.

What makes AIA different from quant funds, which have done systematic, data-driven investing for decades?

The whole thing is focused on reasoning rather than, let’s say, quantitative prediction. I wanted to build something that I could interact with, that could teach me about how the world works and what it’s seeing, and so we built something where it’s not trying to predict the next market move per se, at least not directly. It’s trying to understand what the cause-effect relationships are in the world, draw out that causal map and then use that to predict what’s next.

If I sit down with clients and explain why we hold a position, we can hold AIA to that same standard. It should be a reasoning-first kind of thing, and that’s what’s getting better and better.

Would you ever let AIA trade without human intervention?

I don’t see that happening. One of the ways quant models work is just being on very short time frames where you can make up for the lack of reasoning with sample size. I would say that has its own problems, but to a certain degree, that’s the case. And you’re seeing more and more development of AIs at that time frame and AIs making their own decisions at that time frame, both with some risks to markets and obviously some benefits. That’s not something we’re currently touching.

Does Bridgewater build kill switches or something similar into its systems?

Definitely. At any point where it deals with the outside world, those all have the ability to sort of make sure it’s not doing something it shouldn’t. So those are essentially kill switches. Obviously, you give up something by not letting it do that. I think that choice still makes sense.

The thing the AI would most like to do, if you look at our AI in the lab, it would like to source its own data. Because it can do that very quickly. So that’s a question: Should it be able to source its own data or not, and what are the pros and cons?

For now, anyway, anything we use in production, we’ll make sure the data acquisition is OK’d by humans. And then all of the risk controls and execution are human-driven algorithms, not AI-driven algorithms.

Lastly, from an investing perspective, what’s your view on the AI trade?

We thought this was an incredible trade two years ago. A lot of it is now priced in. We have modeled all the AI data centers that are being built in the world and what components are likely to go into them and what that means for sales all the way out to 2028. We’re starting our 2029 model. We have a big system to understand what’s going on.

We still think the market is probably underestimating a little bit what will be built in 2028, but it’s close, and that assumes no significant disruption. Obviously, the regulation thing could be something, and funding could be a major disruption. You have to get a massive amount of funding, and you’re having trouble swallowing the funding this year. It’s going to be more than double that funding next year. There’s some execution risk on building out these data centers, and there’s literally the labs that take 40% of the build-out for training right now, potentially slowing down those training runs.

If you have the AI, you need to support the level of those valuations. You also have to imagine that it’s disruptive in many ways—disruptive even to the process of building AI, [and] potentially to the semiconductor process as well. So the rate of change that you might have on what those components are, and how those assets depreciate and so on, is still a risk.

Overall, we have a very small position on the AI build-out at this point and are much more interested in the disruption and adoption trades now.

To be clear, I don’t think it’s a bubble. I think it’s realistically pricing in what’s happening, but it’s not this incredible opportunity either—at least the picks and shovels elements of the AI trade.

The Information : OpenAI Is Close To Solving Another Millennium Prize Math Probl

OpenAI Is Close To Solving Another Millennium Prize Math Problem

Remember when OpenAI landed in hot water earlier this month after mathematicians accused the company of trying to steal their thunder for solving an ultra-difficult math problem? (I know it feels like a million years ago given all the news cycles since then.)

Well, it turns out OpenAI is close to solving another math problem from the Millennium Prize Problems, a set of seven famous math challenges including that earlier “Navier-Stokes existence and smoothness problem,” according to a person with knowledge of the solution.

Employees expect the next problem, known as the Hodge Conjecture, to be solved relatively soon, the person said. The Hodge Conjecture asks whether certain geometric features of shapes defined by polynomial equations can always be described using simpler algebraic pieces. It could take the company longer to announce the solution, though, because it’s trying to figure out how to collaborate with the math community to make the announcement without triggering another PR nightmare, the person said.

Why is OpenAI interested in solving these obscure math problems in the first place? After all, they’re not cheap to solve: it likely took millions of dollars to solve the original Navier-Stokes problem. (OpenAI used a variant of its next pre-trained model, codenamed “Doug,” to solve that problem, the person said.)

However, some OpenAI researchers believe that math is the natural next area for its models to tackle after software engineering. Both domains have similar characteristics: they both require step-by-step logical reasoning and produce answers that can often be automatically checked for correctness. Some researchers even believe that the kind of automation that took over software engineering over the last year will happen to mathematics in the next six to nine months.

Additionally, solving hard math problems also furthers AI developers’ efforts to automate machine learning research, which involves a lot of math. Such automation is part of their effort to get to a point where the AI can develop new AI, known as recursive self improvement.

Testing frontier models’ ability to solve never-before-solved math problems also helps researchers understand how far they’ve advanced and their complex reasoning capabilities. If they’re able to solve hard questions like Navier-Stokes and the Hodge Conjecture, it could be a sign that they could solve similarly difficult questions in other fields like biology or chemistry.

And, it doesn’t hurt that such announcements (when they don’t come with outraged mathematicians) give OpenAI shiny new milestones to tout in the race towards superintelligent AI.


Unsolved

The answer to this conjecture determines how much of the topology of the solution set of a system of algebraic equations can be defined in terms of further algebraic equations. The Hodge conjecture is known in certain special cases, e.g., when the solution set has dimension less than four. But in dimension four it is unknown.

In the twentieth century mathematicians discovered powerful ways to investigate the shapes of complicated objects. The basic idea is to ask to what extent we can approximate the shape of a given object by gluing together simple geometric building blocks of increasing dimension. This technique turned out to be so useful that it got generalized in many different ways, eventually leading to powerful tools that enabled mathematicians to make great progress in cataloging the variety of objects they encountered in their investigations. Unfortunately, the geometric origins of the procedure became obscured in this generalization. In some sense it was necessary to add pieces that did not have any geometric interpretation. The Hodge conjecture asserts that for particularly nice types of spaces called projective algebraic varieties, the pieces called Hodge cycles are actually (rational linear) combinations of geometric pieces called algebraic cycles.

WSJ : Mark Walter, Todd Boehly to Sell Stake in Chelsea for $1.3 Billion Clearla

Mark Walter, Todd Boehly to Sell Stake in Chelsea for $1.3 Billion
Clearlake Capital set to increase its majority holding in Premier League soccer team

  • Mark Walter and Todd Boehly agreed to sell their combined 25% stake in Chelsea to majority owner Clearlake Capital for about $1.27 billion.
  • The transaction values the English soccer team at about £5 billion, including debt, and will hand Walter and Boehly almost $650 million each.
  • Clearlake’s greater control of Chelsea paves the way for a decision on building a new stadium or redeveloping Stamford Bridge.

Mark Walter and Todd Boehly have agreed to sell their combined 25% stake in English soccer team Chelsea in a deal that will hand the two billionaires around $650 million each.

Chelsea said late Wednesday that Walter and Boehly were selling their holdings to Clearlake Capital, the California-based private-equity firm that is already the team’s majority owner. Existing shareholder Hansjorg Wyss will retain his minority holding as part of the deal.

Clearlake is paying about £950 million, equivalent to roughly $1.27 billion, to buy out Walter and Boehly in a transaction that values Chelsea at about £5 billion, including debt, according to a person familiar with the matter.

Walter and Boehly each own about 12.5% of Chelsea, meaning they are set to split the proceeds equally and generate a small profit on the deal. During their time as part-owners, Boehly served as chairman and the main face of the club’s ownership, while Walter took a more passive role and rarely attended matches.

The Boehly-Clearlake group acquired Chelsea in 2022 from Russian billionaire Roman Abramovich for almost £4.3 billion after the oligarch was sanctioned by the U.K. over his ties to the Kremlin.

Boehly was reviled by Chelsea’s supporters but took the criticism in good humor, saying it was par for the course of being the team’s chairman. Shortly after buying the club, he told a business conference he had no idea what made a good soccer player, but that “Chelsea is probably the biggest brand that one can own in sports worldwide.”

For the last couple of years, Boehly and Clearlake have held on-and-off-again sale talks amid rising tensions within the ownership group. Clearlake’s greater control of the London-based team now paves the way for a decision on the hefty investment of either building a new stadium or redeveloping Stamford Bridge.

For Walter, the deal comes at an opportune time. Federal regulators are probing the businessman’s insurance empire and he has been refinancing assets.

Authorities are examining loans that insurance companies controlled by Walter made that ultimately helped fund his other business interests. They are seeking to determine whether there was any fraud around the transactions. Those insurance companies have said they are now working to eliminate most of that lending.

Walter’s conglomerate, TWG Global, has said there was no fraud at either his Wall Street firm Guggenheim Partners or at his insurers.

Last month Walter agreed to sell his majority stake in the Los Angeles Lakers, in a deal that values the basketball team at $12.5 billion. That agreement comes only a year after Walter acquired the stake.

Ahead of the Chelsea deal, a spokesperson for Walter had said the billionaire didn’t initiate the transaction, which had been in the works for some time.

Boehly and Walter have invested alongside one another for more than a decade, having worked together at Guggenheim until 2015. In 2012, they were in a bidding group that bought the Los Angeles Dodgers for $2.15 billion, then the highest price paid for a sports team.

The deal was paid in large part by funding from insurance companies they owned with Guggenheim, causing controversy but also igniting a wave of interest from private-equity firms to tap in to sports cash flows.

Evercore was lead financial adviser on the transaction. The Raine Group, BDT&MSD Partners, and BofA Securities served as financial advisers to Clearlake. Goldman Sachs is serving as financial adviser to the sellers.

WSJ : The Italian Resort Area Selling Yacht Life, Longevity—and $100 Million Vil

The Italian Resort Area Selling Yacht Life, Longevity—and $100 Million Villas
Wealthy Italians have long been drawn to Costa Smeralda, but local real-estate pros say they’ve seen an uptick in interest from U.S. buyers

Tradition sets the tone in Italy’s exclusive coastal resorts, from quaint Portofino to the atmospheric island of Capri. But change is coming to the most exclusive of them all: Costa Smeralda, on the jagged northeast coast of Sardinia, known for its sandy beaches, turquoise waters and yachting culture. The area has long had a notoriously short season—weeks, or even days, in July and August—to make the most of peak yachting and the warmer waters. But as second-home owners are joined by a growing number of primary-home owners working remotely, the season has begun to extend into spring and fall, and beyond. Meanwhile, a market that included just about anyone but Americans is now seeing an influx of U.S. interest, real-estate agents say. This spring, Delta Air Lines inaugurated the first direct links between the U.S. and northeast Sardinia, with seasonal flights from New York’s JFK to Olbia Costa Smeralda Airport.

The Draw

Natural beauty and Midcentury Modernism
Costa Smeralda (the “emerald coast”) runs north from Olbia along a series of scenic coves and promontories. Dating back to the 1960s, when a roughly 35-mile stretch of coastline was first developed, the area was built up in a rustic iteration of Midcentury Modernism that has determined the style of homes there ever since. Over the years, the term Costa Smeralda has become synonymous with the glamorous northeastern coast of Sardinia as a whole.

A famous crowd
Costa Smeralda has drawn summer residents including Italy’s former prime minister, the late media mogul Silvio Berlusconi, and members of Italy’s Mentasi family, who once controlled the San Pellegrino mineral-water brand. More recently, A-list summer visitors have included Jeff Bezos and Lauren Sánchez Bezos, supermodel Naomi Campbell, and Leonardo DiCaprio.

The yachting life
Yachts play a central role in this market, say agents. Alexander Christopher of Lionard Luxury Real Estate says around two-thirds of his prospective buyers come to viewings by yacht or yacht tender. And one recent American client, he adds, considered leaving a cliff-top viewing by wingsuit.

At the height of the Mediterranean yachting season, some wealthy homeowners sleep on their anchored yachts, while using their eight- and nine-figure homes primarily for entertaining, says Diletta Giorgolo of Italy Sotheby’s International Realty.

The longevity factor
A cluster of inland Sardinian villages with a high rate of centenarians first gave rise to the so-called Blue Zone phenomenon. In and around the resort area, hotels offer longevity expeditions that highlight the island’s distinctive sheep-milk cheeses, now valued for their bioactive compounds, and polyphenol-rich red wine. And real-estate agents say that the Blue Zone label has become a selling point for luxury buyers.

The Big Numbers

In the fourth quarter of 2025—the most recent data available—Knight Frank’s prime residential index for Costa Smeralda, representing growth among the top 5% of properties, was averaging $2,412 per square foot, up nearly 26% since the prepandemic levels of 2019. By comparison, Portofino was $1,375 per square foot in fourth quarter of 2025, while Lake Como was $1,228 per square foot.

In 2025, Italy Sotheby’s International Realty sold a three-villa compound in Costa Smeralda’s Romazzino for about $189.18 million.

Who is buying
Wealthy Italians from Milan and Rome and other Europeans remain a constant in the area, but “we are seeing more and more U.S. buyers,” says Giorgolo. U.S. queries have tripled since 2022 at ImmobilSarda/Christie’s International Real Estate, according to Julia Bracco, head of the agency’s Costa Smeralda Office.

More buyers are now interested in living in the region fulltime, real-estate agents said. The Sardinia International School—a private academy serving the area’s new wave of wealthy residents—opened in 2025.

The idea of leading “a slower life” was what drew Luca and Nadina Piperno to the wider area, Nadina says. The recent Swiss transplants closed this summer on a property in the countryside near Olbia for about $1.6 million. Luca, 36, is a freelance CPA, while Nadina, 34, will stay at home with the couple’s two small children. Long-term plans for their inland Sardinian life include selling oil from their own olive grove and possibly sending their children to the Sardinia International School.

What they’re buying
Properties with private coastal acreage in prime Costa Smeralda can sell for over $100 million, while midsize villas with sea views can start at around $17 million. Pieds-à-terre near Porto Cervo, a small village that balloons into an upscale playground in high season, can be had for around $1.44 million.


On The Market


Punte Volpe
$57.7 Million
10 bedrooms | 12 bathrooms
7,000 sq. ft. | 4.7 acres

ITALY SOTHEBY’S INTL. REALTY
This waterfront compound includes a main house with a primary suite located in a tower. A private pathway leads directly to the shoreline. Italy Sotheby’s International Realty is an agency handling the sale.


Porto Rotondo
$40.4 Million
10 bedrooms | 8 bathrooms
10,800 sq. ft. | 1.98 acres

TIZIANO CANU
Designed in the 1970s, this waterfront estate has a main house with terracotta floors and exposed ceiling beams. The swimming pool has sea views. ImmobilSarda/Christie’s International Real Estate is an agency handling the sale.